Non-Hodgkin lymphoma (NHL) represents a diverse group of hematologic cancers. Among the most prevalent subtypes are diffuse large B-cell lymphoma (DLBCL), an aggressive but often curable form, and follicular lymphoma (FL), typically an indolent, relapsing-remitting disease that poses significant long-term management challenges. PTCE’s 2025 Lymphoma Day of Education is designed to equip oncology pharmacists with advanced knowledge of the intricate mechanisms of action, therapeutic targets, and unique toxicity profiles of novel NHL therapies. Kicking off the day, the keynote address will provide a crucial foundation for NHL, delving into the intricate pharmacology of novel NHL therapies, including mechanisms of action, therapeutic targets, and unique toxicity profiles while emphasizing the paramount importance of understanding oncology pharmacology to optimize patient outcomes. Subsequent sessions will offer deep dives into the DLBCL and FL subtypes, covering evolving treatment algorithms in relapsed/refractory disease, with a strong focus on the strategic integration and sequencing of CAR T-cell therapy, bispecific antibodies, and other novel agents. Advanced clinical panel debates will conclude each session, challenging pharmacists to apply their knowledge to real-world cases, operational considerations, and toxicity management.

Accreditation Information

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Each CE broadcast/symposium is approved for application-based credit.

Obtaining Credit

All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.